DSGN · Design Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $13.03
Note written ·
Price against the kill line
19.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $13.03, on record since 11 November 2026. The shares are down 30.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $13.03, 21% over the 11 November 2026 close of $10.77 and above the 200-day average, which would show the shares leading the S&P 500. A Q4 2026 update confirming a registrational path built on blood FXN protein change would also show that.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Free cash flow, four quarters ($M)
- −59.4
- Net cash, cash less debt ($M)
- 209
- Free-cash-flow yield (%)
- −8.9
All filed numbers
What Design Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) |
|---|---|---|
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −74.1 | −20.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +10.7 |
| Operating cash flow ($M) | −59.3 |
| Capital spending ($M) | 0.1 |
| Free cash flow ($M) | −59.4 |
| Cash and short-term investments ($M) | 209 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 209 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 202 |
| Market value ($M) | 671 |
| Enterprise value, market value plus net debt ($M) no debt reported | 462 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 3.3 |
| Free-cash-flow yield (%) | −8.9 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 10.4% of shares outstanding sold short, 12.0 days of average trading to cover, +0.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
Design Therapeutics' shares are more likely to lag the S&P 500 over the next three months. The decision on whether blood frataxin (FXN) protein change can anchor a registrational path for DT-216P2 in Friedreich ataxia is still pending, and a new stock-sale program adds supply. The company's Q4 2026 registrational-plans update settles the case.
DSGN closed at $10.77 on 11 November 2026, 37.6% below its 52-week intraday high of $17.25 set on 29 April 2026. The three-month change is −25.2%, and the close sits below both the 50-day average of $11.88 and the 200-day average of $12.18.
Company news dated 4 November 2026 reported that Design authorized up to $200 million of common stock sales through Jefferies and filed a $300 million mixed securities registration. The shares closed at $9.67 on 5 November 2026, the day the company reported third-quarter results, and recovered to $10.80 on 9 November 2026. On 5 November 2026 RBC Capital Markets kept its Outperform rating and lowered its price target to $19.
Design has not announced regulatory acceptance of blood FXN protein change as an approval endpoint. The 12-week RESTORE-FA results remain guided to Q1 2027. The market price of $10.77 against RBC's $19 target shows how much of the sell-side case the shares have not yet credited.
Bullish and bearish views on Design Therapeutics, Inc.
The bull case on Design Therapeutics, Inc. (DSGN), in brief: biological activity has a measured signal. The bear case: new stock-sale capacity arrived with the results.
Bull case
- Biological activity has a measured signal. Design's 18 May 2026 release reported that whole-blood FXN messenger RNA rose 65% from baseline after four weeks at 1 mg/kg (p < 0.001), with a 6.4-point mean improvement on the modified Friedreich's Ataxia Rating Scale. The Q1 2027 12-week results test whether the increase persists.
- Safety record is clean so far. The same release reported no serious adverse events or treatment discontinuations, and transient mild-to-moderate liver enzyme (ALT) elevations in three patients.
- Timelines held in the third-quarter release. Design's release of 5 November 2026 kept the registrational-plans update in Q4 2026 and the 12-week RESTORE-FA data in Q1 2027. No new delay was announced.
- Cash funds current work. Design reported $208.6 million in cash, equivalents and investment securities at 30 September 2026, against $207.4 million at 30 June 2026.
- Sell-side target sits far above the price. RBC's Outperform rating and $19 target of 5 November 2026 compare with the $10.77 close on 11 November 2026.
Bear case
- New stock-sale capacity arrived with the results. Company news on 4 November 2026 reports an at-the-market program, meaning sales of stock at prevailing prices through an agent, of up to $200 million, plus a $300 million mixed registration. Sales under it would add shares to a stock that is down 25.2% over three months.
- Cash is steady only because stock is sold. Cash of $208.6 million at 30 September 2026 compares with $207.4 million at 30 June 2026, while third-quarter net loss was $20.3 million, or $0.32 per share. Research and development was $16.9 million and general and administrative expense $5.3 million (Design's third-quarter 2026 results).
- Endpoint acceptance is unproven. The 3 August 2026 update made blood FXN protein change the primary efficacy endpoint of a 10-patient, 12-week RESTORE-FA cohort. No regulator has publicly accepted that measure for approval.
- Analyst target moved down. RBC lowered its target to $19 on 5 November 2026 while keeping Outperform, one day after the financing news.
- A separate program slipped. DT-168 data moved into 2027 on 3 August 2026 because of eye-dropper supply delays, and DT-818 data are also guided to 2027. No clinical readout other than DT-216P2 arrives before 2027.
Price setup
DSGN closed at $10.77 on 11 November 2026, from $10.65 on 10 November 2026 and $10.80 on 9 November 2026. The 50-day average is $11.88 and the 200-day average is $12.18, both on adjusted daily closes, so the shares sit below both.
The 5 November 2026 close of $9.67 is the lowest of the closes from 4 November 2026 through 11 November 2026. The shares have since recovered above their 4 November 2026 close of $10.63.
The 52-week intraday high is $17.25 on 29 April 2026. The 52-week closing low is $7.06 on 13 November 2025. The close of $14.39 on 13 August 2026 is the reference for the three-month decline.
Share-issuance capacity of up to $200 million, authorized on 4 November 2026, is supply that can meet any rally. The next dated price event is the company's guided Q4 update, not a scheduled earnings report.
Catalysts ahead
- ~15 December 2026 (est.): DT-216P2 registrational-plans update, guided to Q4 2026. Shows whether blood FXN protein change has a regulatory path to approval; this is the event that settles the call.
- ~31 March 2027 (est.): 12-week RESTORE-FA results, guided to Q1 2027. Tests whether the FXN increase seen at four weeks persists.
What would change the view
A daily close above $13.03, 21% over the 11 November 2026 close of $10.77 and above the 200-day average, which would show the shares leading the S&P 500. A Q4 2026 update confirming a registrational path built on blood FXN protein change would also show that.
What it trades with
DSGN trades as a single-asset, clinical-stage biotech. Its price depends on company-specific regulatory and trial news and on small-cap biotech risk appetite. Other Friedreich ataxia and rare-disease developers react to the same regulatory precedents, but this note rests on no measured correlation with any peer.
The evidence, claim by claim (6)
- DSGN closed at $10.77 on 11 November 2026, 37.6% below its 52-week intraday high of $17.25 (29 April 2026); the three-month change is −25.2%. Adjusted daily closes · as of
- Third-quarter 2026 net loss was $20.3 million ($0.32 per share); R&D $16.9 million; G&A $5.3 million; cash, equivalents and investment securities $208.6 million. Design Therapeutics Q3 2026 results, via BiopharmaWatch and Panabee summaries · as of
- Design kept the registrational-plans update in Q4 2026 and 12-week RESTORE-FA data in Q1 2027; DT-818 and DT-168 data are expected in 2027. Design Therapeutics Q3 2026 results, via BiopharmaWatch summary · as of
- Design authorized up to $200 million of common stock sales through Jefferies and filed a $300 million mixed securities registration. Company news headlines · as of
- RBC Capital Markets maintained Outperform on Design and lowered its price target to $19. RBC Capital Markets, reported 5 November 2026 · as of
- After four weeks at 1 mg/kg of DT-216P2, whole-blood FXN mRNA rose 65% from baseline (p < 0.001) and mean mFARS improved 6.4 points; no serious adverse events were reported. Design Therapeutics RESTORE-FA four-week data release · as of
Sources
Related · shared themes
TVTX
Travere Therapeutics
Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to…
ABEO
Abeona Therapeutics
Abeona Therapeutics' ZEVASKYN revenue grew 18% to $13.5 million in the third quarter but missed estimates, and a $3.75-a-share placement…
ARCT
Arcturus Therapeutics Holdings
Arcturus Therapeutics has cash into 2028 but no dated FDA path for ARCT-810 and no dated Phase 3 decision for ARCT-032, so the shares are…
MGTX
MeiraGTx Holdings
MeiraGTx's shares are more likely to lag the S&P 500 over three months: the US filing for its gene therapy bota-vec slipped to the first…
See also · stocks to watch